Literature DB >> 23887360

A novel C5a-neutralizing mirror-image (l-)aptamer prevents organ failure and improves survival in experimental sepsis.

Kai Hoehlig1, Christian Maasch, Nelli Shushakova, Klaus Buchner, Markus Huber-Lang, Werner G Purschke, Axel Vater, Sven Klussmann.   

Abstract

Complement factor C5a is a potent proinflammatory mediator that contributes to the pathogenesis of numerous inflammatory diseases. Here, we describe the discovery of NOX-D20, a PEGylated biostable mirror-image mixed (l-)RNA/DNA aptamer (Spiegelmer) that binds to mouse and human C5a with picomolar affinity. In vitro, NOX-D20 inhibited C5a-induced chemotaxis of a CD88-expressing cell line and efficiently antagonized the activation of primary human polymorphonuclear leukocytes (PMN) by C5a. Binding of NOX-D20 to the C5a moiety of human C5 did not interfere with the formation of the terminal membrane attack complex (MAC). In sepsis, for which a specific interventional therapy is currently lacking, complement activation and elevated levels of C5a are suggested to contribute to multiorgan failure and mortality. In the model of polymicrobial sepsis induced by cecal ligation and puncture (CLP), NOX-D20 attenuated inflammation and organ damage, prevented the breakdown of the vascular endothelial barrier, and improved survival. Our study suggests NOX-D20 as a new therapeutic candidate for the treatment of sepsis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23887360      PMCID: PMC3863792          DOI: 10.1038/mt.2013.178

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  49 in total

1.  Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis.

Authors:  Tom Sprong; Petter Brandtzaeg; Michael Fung; Anne M Pharo; E Arne Høiby; Terje E Michaelsen; Audun Aase; Jos W M van der Meer; Marcel van Deuren; Tom E Mollnes
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

2.  Complement-induced impairment of innate immunity during sepsis.

Authors:  Markus S Huber-Lang; Ellen M Younkin; J Vidya Sarma; Stephanie R McGuire; Kristina T Lu; Ren Feng Guo; Vaishalee A Padgaonkar; John T Curnutte; Richard Erickson; Peter A Ward
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

Review 3.  Sepsis, systemic inflammatory response, and multiple organ dysfunction: the mystery continues.

Authors:  Donald E Fry
Journal:  Am Surg       Date:  2012-01       Impact factor: 0.688

4.  Long-term cognitive impairment and functional disability among survivors of severe sepsis.

Authors:  Theodore J Iwashyna; E Wesley Ely; Dylan M Smith; Kenneth M Langa
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

5.  Functions of the complement components C3 and C5 during sepsis.

Authors:  Michael A Flierl; Daniel Rittirsch; Brian A Nadeau; Danielle E Day; Firas S Zetoune; J Vidya Sarma; Markus S Huber-Lang; Peter A Ward
Journal:  FASEB J       Date:  2008-06-27       Impact factor: 5.191

6.  C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease.

Authors:  Nelli Shushakova; Julia Skokowa; Jurriaan Schulman; Ulrich Baumann; Jörg Zwirner; Reinhold E Schmidt; J Engelbert Gessner
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

7.  Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation.

Authors:  Julia Skokowa; Syed R Ali; Olga Felda; Varsha Kumar; Stephanie Konrad; Nelli Shushakova; Reinhold E Schmidt; Roland P Piekorz; Bernd Nürnberg; Karsten Spicher; Lutz Birnbaumer; Jörg Zwirner; Jill W C Claassens; Josef S Verbeek; Nico van Rooijen; Jörg Köhl; J Engelbert Gessner
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

8.  Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist.

Authors:  A J Strachan; I A Shiels; R C Reid; D P Fairlie; S M Taylor
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

9.  Derivation of RNA aptamer inhibitors of human complement C5.

Authors:  G Biesecker; L Dihel; K Enney; R A Bendele
Journal:  Immunopharmacology       Date:  1999-05

10.  Immunodesign of experimental sepsis by cecal ligation and puncture.

Authors:  Daniel Rittirsch; Markus S Huber-Lang; Michael A Flierl; Peter A Ward
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

View more
  30 in total

Review 1.  Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective.

Authors:  M A Khan; J L Hsu; A M Assiri; D C Broering
Journal:  Clin Exp Immunol       Date:  2015-11-05       Impact factor: 4.330

Review 2.  Necroinflammation in Kidney Disease.

Authors:  Shrikant R Mulay; Andreas Linkermann; Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2015-09-02       Impact factor: 10.121

3.  Development of Autologous C5 Vaccine Nanoparticles to Reduce Intravascular Hemolysis in Vivo.

Authors:  Lingjun Zhang; Wen Qiu; Stephen Crooke; Yan Li; Areeba Abid; Bin Xu; M G Finn; Feng Lin
Journal:  ACS Chem Biol       Date:  2017-01-12       Impact factor: 5.100

Review 4.  Recent Advances in Aptamers Targeting Immune System.

Authors:  Piao-Ping Hu
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

Review 5.  New milestones ahead in complement-targeted therapy.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Semin Immunol       Date:  2016-06-16       Impact factor: 11.130

6.  Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model.

Authors:  Z Shao; T Nishimura; L L K Leung; J Morser
Journal:  J Thromb Haemost       Date:  2015-05-10       Impact factor: 5.824

7.  Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects.

Authors:  Daniel Ajona; Carolina Zandueta; Leticia Corrales; Haritz Moreno; María J Pajares; Sergio Ortiz-Espinosa; Elena Martínez-Terroba; Naiara Perurena; Fernando J de Miguel; Eloisa Jantus-Lewintre; Carlos Camps; Silvestre Vicent; Jackeline Agorreta; Luis M Montuenga; Ruben Pio; Fernando Lecanda
Journal:  Am J Respir Crit Care Med       Date:  2018-05-01       Impact factor: 21.405

8.  Intravitreal inhibition of complement C5a reduces choroidal neovascularization in mice.

Authors:  Claudia Brockmann; Tobias Brockmann; Sabrina Dege; Catharina Busch; Norbert Kociok; Axel Vater; Sven Klussmann; Olaf Strauß; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-16       Impact factor: 3.117

9.  A novel CGRP-neutralizing Spiegelmer attenuates neurogenic plasma protein extravasation.

Authors:  K Hoehlig; K W Johnson; E Pryazhnikov; C Maasch; A Clemens-Smith; W G Purschke; S Vauléon; K Buchner; F Jarosch; L Khiroug; A Vater; S Klussmann
Journal:  Br J Pharmacol       Date:  2015-03-27       Impact factor: 8.739

10.  Anti-inflammatory interventions-what has worked, not worked, and what may work in the future.

Authors:  Fatemeh Fattahi; Peter A Ward
Journal:  Transl Res       Date:  2015-08-14       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.